KCNQ2 and depressive disorder: Arketamine and (2R,6R)-HNK increase the in vitro production of KCNQ2 mRNA (codes for potassium voltage-gated channel subfamily Q member 2) implicated in depression [97], in ventral hippocampus glutaminergic neurons, adding yet another potential mechanism of anti-depressant activity [97,98].